Form D · Biotechnology
Novasenta Inc.
Pittsburgh, PA · CIK 0001936994
Offering snapshot reported Feb 6, 2024 · SEC filing
- Reported sold
- $15M Offering amount: $30M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 6, 2024 | Initial | $15,000,000 | No comparison | 1 | SEC filing |
| Jul 8, 2022 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-504482
Source: Form D, filed Feb 6, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeanne Cunicelli | Director |
| Greg Delgoffe | Director |
| Matthias Kleinz | Director |
| Mani Mohindru | Director, Executive |
| David Moore | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
350 Technology Drive Suite 501
Pittsburgh, PA, 15219
Pittsburgh, PA, 15219